Gotham Therapeutics is a biotechnology company discovering drugs that target the epitranscriptomics machinery that modifies RNA that is headquartered in New York City, New York and was founded in 2017 by Samie Jaffray. The companies drugs in development can potentially treat cancer, auto-immune diseases, and neurodegenerative diseases according to the company's website.
On October 10, 2018 Gotham Therapeutics announced raising $54 million in series A funding from Versant Ventures (lead investor), SR One, and Forbion Capital Partners. The partner of Versant Ventures, Carlo Rizzuto, made the following statement about his firms decision to invest in Gotham Therapeutics:
After following the developments in the RNA drug discovery field for a number of years, we felt this was the right time to build a company that could capitalize on translating the scientific discoveries into a whole new class of drug candidates. With our initial investment, the Gotham team constructed a platform able to validate critical links between specific types of RNA modifications and disease biology. We look forward to advancing a number of drug candidates with this new round of financing.